Saturday 17 October 2026
Export NKTX’s income statement to Excel — free account
Nkarta, Inc.
NKTX Healthcare Biotechnology
In the quarter to June 2026, EPS fell 74.2% and free cash flow fell 29.2%, each against the same quarter a year earlier.
1.80
0.13
−6.74%
Follow NKTX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (38.76%) | (30.07%) | (28.90%) | (26.69%) |
+8 more TTM periods Free account |
|
| (29.86%) | (23.72%) | (22.99%) | (21.39%) | ||
ROIC |
(127.22%) | (131.14%) | (211.53%) | (137.17%) | |
Return on Tangible Assets |
(53.03%) | (35.43%) | (31.83%) | (30.32%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(1.26) | (1.19) | (1.22) | (1.26) | |
Free Cash Flow |
(93.90) | (88.39) | (89.91) | (93.55) | |
Capital Expenditures |
(1.15) | (1.10) | (1.21) | (1.75) | |
| Other line items | |||||
Cash ROIC |
(21.81%) | (17.12%) | (15.27%) | (15.08%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.79 | 0.87 | 0.85 | 0.89 | |
Depreciation/Fixed assets |
0.12 | 0.08 | 0.07 | 0.05 | |
Capex/Depreciation |
(0.17) | (0.20) | (0.26) | (0.49) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.25) | (1.18) | (1.20) | (1.24) | |
Capex per Share |
(0.02) | (0.01) | (0.02) | (0.02) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates